2025 Annual NMD4C Early-Career Awards is Open for Applications
We are excited to announce the opening of our third annual early-career awards competition!
This program provides three awards, celebrating excellence and contribution to the neuromuscular field by early career investigators across both clinical and basic science streams. The three categories included in the competition are Early Career Biomedical Researcher of the Year, Early Career Clinical Researcher of the Year, and Publication of the Year.
Through these awards, we provide a method of recognizing outstanding achievement by early career neuromuscular researchers and clinicians on behalf of the Canadian neuromuscular community. Recipients receive a tangible accolade to bolster their academic CVs in pursuit of future academic appointments and grant applications. This award program is a part of the network’s broader strategy to provide support for Canadian early-career neuromuscular investigators.
The nomination deadline for the 2025 awards cycle is January 15th, 2025, with applicants notified of outcomes in February 2025. We encourage self-nominations, as well as nominations from colleagues! If you or someone you know has made an outstanding achievement to the Canadian neuromuscular community, we encourage you to apply for one of our awards!
Learn more about the competition!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.